StandoutStocks.com: "Stocks that Standout" picks for today are: CEGE, EDWY, JAVA, SIAL

StandoutStocks.com "Stocks that Standout" picks for today are: Cell Genesys, Inc. (NASDAQ: CEGE), eDOORWAYS Corporation (PINKSHEETS: EDWY), Sun Microsystems, Inc. (NASDAQ: JAVA), Sigma-Aldrich (NASDAQ: SIAL)

Visit Us On Twitter and Facebook: http://twitter.com/StandoutStocks http://www.facebook.com/people/Standout-Stocks/547603354

Sign-up for our FREE Stock Alerts AND AWARD WINNING NEWSLETTER at www.Standoutstocks.com

Jun 23, 2009 -- Cell Genesys, Inc. (NASDAQ: CEGE) today reported that over 98% or approximately $67 million aggregate principal amount of its 3.125% convertible bonds were tendered in its previously announced exchange offer. The Company offered to exchange all of the $68.3 million aggregate principal amount of its outstanding 3.125% Convertible Senior Notes due in 2011 at a purchase price for each $1,000 principal amount of (i) $500, plus accrued interest, (ii) $140 worth of common stock equal to approximately 221 shares of common stock, and (iii) $310 of new 3.125% Convertible Senior Notes due in May 2013. Upon settlement of the exchange offer, approximately $1 million of the original 3.125% Convertible Senior Notes due in 2011 remain outstanding and $20.8 million of new 3.125% Convertible Senior Notes 2013 notes are expected to be issued. In connection with the exchange, participants in the exchange are expected to be issued approximately 13.8 million shares of common stock, $33.5 million in cash and $0.3 million in accrued interest. The Company expects to settle the exchange offer as soon as practicable.

Upon settlement of the exchange offer, the Company's cash balance is expected to be approximately $36 million and 109.6 million shares of stock are expected to be outstanding.

Under the terms of a settlement agreement entered into on May 10, 2009, Tang Capital Partners, LLC, agreed to withdraw the creditor derivative lawsuit it filed against the Company on May 5, 2009 following consummation of the exchange offer.

As previously announced, the Company has implemented a substantial restructuring plan and continues to explore strategic alternatives, including merger with or acquisition by another company, additional restructuring, allocation of its remaining resources toward other biopharmaceutical product areas, which may include the acquisition or licensing of other product candidates, and liquidation of the Company. The Company engaged Lazard Freres & Co, LLC in connection with the evaluation of strategic alternatives.

As part of its restructuring plan and in pursuit of the above strategic alternatives, the Company has taken the following steps:

-- Reduced the Company's staff to 9 employees who maintain financial and corporate records and work with the Board of Directors to pursue strategic alternatives for the Company. As previously announced, the Company eliminated all research and development, manufacturing, clinical and regulatory activities and personnel.

-- Relocated corporate operations to 3,000 square feet of short-term office space in South San Francisco; all other facility leases were terminated and vacated including for the Company's head office and research facility in South San Francisco, California and for its manufacturing facility in Hayward, California.

-- Ended the development of GVAX immunotherapy for prostate cancer and oncolytic virus therapy products, closed or transferred all IND filings with the FDA and closed out all clinical trial sites and contracts related to those activities. The Company has transferred the GVAX immunotherapy for prostate cancer IND and remaining clinical product to investigators at Johns Hopkins University while maintaining its commercial rights to this and other GVAX therapy products. No activity, however, is currently underway at the Company in these areas.

-- Terminated the Company's collaborative agreement with Takeda Pharmaceutical Company Limited for GVAX immunotherapy for prostate cancer.

-- Substantially reduced the number of patents and terminated a number of license agreements in order to reduce costs. Included among the terminated agreements were those relating to the development and commercialization of oncolytic therapies with Novartis Pharma, AG and certain affiliates as well as a gene activation technology license agreement with sanofi-aventis.

-- Entered into a warrant exchange agreement as of May 17, 2009 with a warrant holder in order to facilitate pursuit of strategic alternatives and to potentially reduce the cash payment if the Company were to enter into certain types of transactions. As a result of this exchange, the Company issued 8 million shares and eliminated approximately 93% of the shares issuable upon exercise of this warrant.

-- Terminated a Committed Equity Financing Facility with Kingsbridge Capital, Ltd., signed in 2007, due to a substantial fall in our stock price below the minimum purchase price of $1.75 per share.

-- Repurchased through private transactions and a previously completed tender offer, $76.7 million in face value of the Company's 3.125% convertible notes due in November, 2011 at 60% discount to face value.

Jun 22, 2009 -- eDOORWAYS Corporation (PINKSHEETS: EDWY) Chairman & CEO Mr. Gary Kimmons encourages shareholder communication through the company's corporate blog indicating that it is a platform of transparency -- partly fueling shareholder confidence.

"We believe initiating the Corporate Blog was one of the best things the company could have done to foster transparency," said Kimmons. "We receive hundreds of hits daily and field dozens of comments. Good, bad or indifferent we respond to any inquiry, where appropriate or legally permissible, with a sense of responsibility and detail that shareholders deserve. As a developing company trading within the dynamics of any economy, investors need to know the facts in order to make educated decisions that result in long term investments in any company. That's what we aspire to -- achieving long term holders of eDOORWAYS stock."

Over the past eight months, eDOORWAYS has administered a communication campaign aimed at the accurate and most transparent dissemination of company information and the procurement of good company/shareholder relations. This includes shareholder letters, info packets, conference calls and a whole host of other communiques with the corporate blog seemingly the most prominent. According to people close to the company, this approach actually opened the company up to much ridicule and hard questions to answer. However, due to the company's commitment to stand behind the truth and its viability, eDOORWAYS seems to have garnered strong shareholder support.

With next week's shareholder conference call expected to announce extremely favorable information regarding this year's launch of the company's highly anticipated Web 3.0 platform, shareholders have been using the corporate blog as an open line of communication with the company. A mix of high praises and hard line questions posted to the blog seem to reflect shareholders simply seeking reaffirmation of their current positions -- increasing correspondence with the company tenfold. Blog comments have mounted from a handful of monthly posts to dozens of comments weekly. Phone calls, emails and info packet requests have also increased significantly.

"We welcome it!" stated Kimmons. "We are the 'real deal' and as such, willing to do whatever it takes to convey these simple realities to the public. eDOORWAYS will launch. The platform will begin generating revenue within the first four months of our launch. We're likely to have the second 'doorway' operating shortly after the initial launch which will positively affect our initial revenue projections."

Optimism at eDOORWAYS continues to grow as the company prepares for the June 29th conference call to announce its 2009 launch date. People close to the company expect to see blog correspondence increase as the market continues to show EDWY good favor.

Jun 23, 2009 -- Sun Microsystems, Inc. (NASDAQ: JAVA) today announced new products that enhance the Sun(TM) Constellation System, including a new InfiniBand (IB) Quad Data Rate (QDR) switch for optimal cluster interconnect performance, new Sun(TM) HPC Software Linux Edition 2.0 for faster and simpler cluster deployment, and Sun(TM) Grid Engine 6.2 Update 3 for ease of management. Sun is also demonstrating its storage leadership for HPC, with new enhancements to the Lustre(TM) file system, which manages data on nearly two-thirds of the Top 50 supercomputers and seven of the Top 10 supercomputers on the just-released Top500 list.

New Open Networking, Software and Sun Storage Bolster Power of Sun Constellation System

Sun is announcing new products today that demonstrate continued innovation and expansion of the Sun Constellation System. Designed using Sun's Open Network Systems architecture, the Sun Constellation System is one of the most integrated and balanced HPC system available today. Highlights include:

-- Sun(TM) Datacenter InfiniBand QDR Switch 648: Delivers extreme density, performance and reduced deployment complexity with up to three times more ports per rack, four and a half times more system bandwidth, and up to 3:1 cable reduction than competitive Double Data Rate (DDR) switch solutions.

-- Sun HPC Software, Linux Edition 2.0: Makes it faster and easier to install Linux-based environments by providing an integrated Linux software stack for HPC solutions, and gives customers a choice of running SUSE 10, CentOS and Red Hat Linux.

-- Lustre 1.8.0: Introduces several robust new features to improve system performance and functionality, including the adaptive timeouts feature, client interoperability feature, OSS read cache feature and Version-based Recovery (VBR).

Sun Constellation System Powers Two of the Top 10 Systems on Top500 List

The Sun Constellation System is expected to power some of the largest HPC systems in the world, with more than two PetaFLOPS of performance already installed or ordered. According to the latest Top500 list released today, Sun increased its overall presence on the list, including two supercomputers in the Top 10 powered by the Sun Constellation System: the Ranger supercomputer at the Texas Advanced Computing Center (TACC) at #8, and the JuRoPa supercomputer at Forschungszentrum Juelich in Germany at #10 -- which is also the most efficient system among the Top 10 supercomputers as measured by the LINPACK benchmark. In addition, nine of the top 10 supercomputers are using Sun Storage technologies, including Lustre and tape storage.

Sun is also announcing new HPC customers today, including:

Toshiba Research Europe recently replaced five racks of obsolete white-box systems with two Sun Blade(TM) 6000 chassis filled with Sun Blade X6450 server modules, powered by Intel(R) Xeon(R) six-core processors. The company is also deploying Sun HPC Software with Linux and Sun Grid Engine software. Toshiba Research Europe is using the new Sun solution for advanced fundamental research in the field of wireless telecommunications.

The University of North Carolina at Chapel Hill (UNC-CH) turned to an HPC solution from Sun to speed its biomedical research and image analysis. The UNC-CH grid -- called the Biomedical Analysis and Simulation Supercomputer (BASS) system -- consists of 17 Sun Fire(TM) X4600 M2 servers, each with 16 2.8GHz Quad-Core AMD Opteron(TM) processor cores. UNC-CH is also deploying a Sun Storage(TM) 6140 array, Sun Storage SL500 modular library system, 45 Sun Ultra(TM) 40 M2 workstations and Sun Grid Engine software.

Sun at ISC 2009

Sun is previewing a range of HPC technologies at the ISC 2009 show (Sun booth #410), such as "Project M2," a future addition to its Sun Datacenter Switch family that will be up to six times more space-efficient than competitive chassis switch solutions while delivering up to twice the systems bandwidth than competitive DDR chassis switch solutions. Sun is also demonstrating a next-generation, high-end Sun(TM) Storage 7000 Unified Storage System, in addition to the upcoming Sun Blade X6240 and Sun Blade X6440 server modules powered by the new Six-Core AMD Opteron processor code-named "Istanbul." The four-socket Sun Blade X6440 server module will deliver up to twice the I/O capacity (142 Gbps) of competing blade and rackmount servers, and up to 12 TeraFLOPS of peak performance when a full set of blades are installed in the Sun Blade 6048 chassis.

Sun Constellation System Sets Records on HPC Benchmarks

The Sun Constellation System delivers top performance on a wide range of compute-intensive, memory-intensive, communication-intensive or I/O-intensive applications, such as weather forecasting (WRF), seismic processing (Reverse Time Migration), molecular modeling (NAMD), and subatomic physics (MILC). The Sun Constellation System was able to achieve scalability efficiencies of nearly 90 percent across these workloads, enabling customers to recognize performance benefits at every level. Moreover, the availability of QDR IB infrastructure offers up to an 80 percent performance boost versus DDR IB on communication-intensive suites in HPCC, such as FFT and PTRANS. Further highlighting the Sun Constellation System's compute capabilities, Sun is announcing four new ground-breaking results on the SPEC CPU2006 benchmark, which is used to gauge a computer's processor, memory architecture and compilers on a variety of real-world compute intensive workloads:

-- The best integer throughput score ever published(1)

-- Top x86 floating point throughput result(1)

-- World speed record on integer-intensive computations(2)

-- World speed record on floating point-intensive computations(2)

HPC Software Solutions

Sun is also announcing a variety of open source software solutions and upgrades to simplify HPC deployments. HPC software announced today includes:

-- Sun(TM) Studio 12 Update 1: Contains new features and enhancements to boost performance and simplify the creation of high-performance parallel applications for the latest multicore x86 and SPARC-based systems running on leading Linux platforms, the Solaris(TM) Operating System (OS) or OpenSolaris(TM). The Sun Studio 12 Update 1 software has set almost a dozen industry benchmark records to date, and in conjunction with the freely available community-based OpenSolaris 2009.06 OS, was instrumental in landing four new ground-breaking SPEC CPU2006 results.

-- Sun HPC ClusterTools 8.2: Provides MPI libraries and Runtime environment based on Open MPI, fully tested and supported by Sun on both Solaris and Linux. The software provides full interconnect support, including IB QDR and IB multi-rail, providing both high performance and scalability required by today's powerful HPC cluster systems.

-- Sun Grid Engine 6.2 Update 3: Improves support for both private and public (Amazon EC2) clouds and adds monitoring of compute clusters and the Service Domain Manager (SDM) from one place.

-- Sun(TM) xVM Ops Center 2.1: Enhances Sun xVM Ops Center by providing key bug fixes, integrating patches, and introducing a number of functional and usability enhancements.

-- Sun(TM) Storage Archive Manager 5.0 and Sun(TM) QFS (SAM-QFS): Introduces new shared file system and archive software features that ease administration and improve shared file system services and archive management.

-- Sun HPC Software, Developer Edition 1.0 for OpenSolaris: Combines the latest Sun HPC developer software and tools with OpenSolaris in an easy to use virtual machine.

About Sun Microsystems, Inc.

Sun Microsystems develops the technologies that power the global marketplace. Guided by a singular vision -- "The Network Is The Computer(TM)" -- Sun drives network participation through shared innovation, community development and open source leadership. Sun can be found in more than 100 countries and on the Web.

Jun 23, 2009 -- Sigma-Aldrich (NASDAQ: SIAL) today announced the release of over 2,300 antibody additions to its Prestige Antibodies(R) powered by Atlas Antibodies product line (www.sigma.com/prestige), bringing the total number of highly validated antibodies to over 6,100. Developed by the Human Proteome Resource, these antibodies are available to customers immediately through an exclusive partnership between Sigma-Aldrich and Atlas Antibodies. Prestige Antibodies can provide significant time and cost savings for researchers because they are optimized on a single protocol, resulting in efficient and effective applications.

This addition to the Prestige Antibodies product line is a step toward the Human Proteome Resource's goal to develop at least one antibody to all 22,000 non-redundant human proteins by 2015.

"With this latest addition to the Prestige Antibodies line, Sigma-Aldrich has significantly expanded our antibody offerings, the latest step in our long-term plan to lead the industry in high-quality antibody content," said Dr. David Smoller, President of Sigma-Aldrich's Research Biotech Business Unit. "Our highly validated Prestige Antibodies are ideal for a number of applications, and with our unique online tools we help scientists figure out how to best incorporate them into prospective experiments."

Prestige Antibodies are supported by the publicly available data of the Human Protein Atlas (HPA), part of HUPO's Human Antibody Initiative. Multiple quality assurance testing steps ensure that Prestige Antibodies are highly specific to their targets. Each Prestige Antibody is also associated with over 500 tissue immunohistochemistry (IHC) images, over 100 cell/line immunocytochemistry (ICC) images, immunofluorescence (IF) and western blotting (WB) data, all publicly accessible via the Human Protein Atlas.

In August 2008, Sigma-Aldrich added over 2,000 Prestige Antibodies to the existing antibody product line. The rapid expansion of the Sigma-Aldrich Prestige Antibodies gives an increasing number of scientists the ability to save resources and facilitate high-throughput applications in proteomics and cell biology research.

Prestige Antibodies can be found on the company website, where customers can search for antibodies via specific gene name and ID, or by selecting individual chromosomes. Prestige Antibodies are also included in Sigma-Aldrich's Your Favorite Gene powered by Ingenuity, an award winning Web-based biological search portal for exploring dynamic gene-based content.

About Sigma-Aldrich

Sigma-Aldrich is a leading Life Science and High Technology company. Its biochemical and organic chemical products and kits are used in scientific research, including genomic and proteomic research, biotechnology, pharmaceutical development and as key components in pharmaceutical, diagnostic and other high technology manufacturing. The Company has customers in life science companies, university and government institutions, hospitals, and in industry. Over one million scientists and technologists use its products. Sigma-Aldrich operates in 38 countries and has 7,800 employees providing excellent service worldwide. Sigma-Aldrich is committed to Accelerating Customer Success through Innovation and Leadership in Life Science, High Technology and Service.

About Atlas Antibodies

Atlas Antibodies was founded in 2006 by researchers at the Royal Institute of Technology (KTH) in Stockholm and the Rudbeck Laboratory, Uppsala University in Uppsala, Sweden. Atlas Antibodies will handle the production, marketing and sales of the antibody products developed and validated in the Human Proteome Resource (HPR) Center. The Human Proteome Resource (HPR) Center is performing a systematic exploration of the human proteome with Affinity (Antibody) based Proteomics, combining high-throughput generation of affinity-purified (mono-specific) antibodies with protein profiling using tissue microarrays. The Human Proteome Resource (HPR) Center is located in Stockholm and Uppsala, Sweden and is running the Swedish Human Protein Atlas (HPA) program. The HPA program generates expression and localization patterns of proteins in a large portion of both normal and cancer human tissues and organs resulting in the antibody-based profiling presented in the publicly available Human Protein Atlas (HPA)). The HPA vision is to enable the systematic generation of quality assured antibodies to all non-redundant human proteins and to use these reagents to functionally explore human proteins, protein variants and protein interactions.

About Standoutstocks.com

Standoutstocks.com has become one of the premier stops for investors who wish to experience huge profits via investing in up-and-coming publicly traded companies.

Standoutstocks.com email report service is free to those investors who sign up on our website. The alert service is designed to notify investors of undervalued and often overlooked stocks. Subscribers are introduced to OTCBB and Pinksheet companies that have the potential of showing increased activity and Standing Out from the rest of the market. To subscribe to this free service, visit the Standout StocksReport home page at www.Standoutstocks.com and select the "join now" button.

Join us at www.standoutstocks.com for a complimentary subscription to the most exciting online financial newsletter on the market.

Disclaimer: Verify all claims and do your own due diligence. Standoutstocks.com profiles are not a solicitation or recommendation to buy, sell or hold securities. Standoutstocks.com is not offering securities for sale. An offer to buy or sell can be made only with accompanying disclosure documents and only in the states and provinces for which they are approved. All statements and expressions are the sole opinion of the editor and are subject to change without notice. Standoutstocks.com is not liable for any investment decisions by its readers or subscribers. It is strongly recommended that any purchase or sale decision be discussed with a financial adviser, or a broker-dealer, or a member of any financial regulatory bodies. The information contained herein has been provided as an information service only. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. It should be understood there is no guarantee that past performance will be indicative of future results. Investors are cautioned that they may lose all or a portion of their investment in this or any other company. In order to be in full compliance with the Securities Act of 1933, Section 17(b), Standoutstocks.com is owned and operated by Standoutstocks.com. Neither Standoutstocks.com nor any of its affiliates, or employees shall be liable to you or anyone else for any loss or damages from use of this e-mail, caused in whole or part by its negligence or contingencies beyond its control in procuring, compiling, interpreting, reporting, or delivering this Web Site or e-mail and any contents. Since Standoutstocks.com receives compensation and its employees or members of their families may hold stock in the profiled companies, there is an inherent conflict of interest in Standoutstocks.com statements and opinions and such statements and opinions cannot be considered independent. Standoutstocks.com and its management may benefit from any increase in the share prices of the profiled companies. Information contained herein contains "forward looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities and Exchange Act of 1934. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical facts and may be "forward looking statements". Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Standoutstocks.com services are often paid for using free-trading shares. Standoutstocks.com may be selling shares of stock at the same time the profile is being disseminated to potential investors; this should be viewed as a definite conflict of interest and as such, the reader should take this into consideration.

Visit us for a full Disclaimer at: www.standoutstocks.com/disclaimer.aspx

For More Information Regarding Standout Stocks, Contact Jason A. Hilton at: New Media Advisors LLC. 1115 E. Main Rochester, Ny 14609 Office: (866)704-0122 Email: Jason@Newmediaadvisorsllc.com

CONTACT: Jason A. Hilton, New Media Advisors LLC Tel: +1 866 704 0122 e-mail: Jason@Newmediaadvisorsllc.com Standoutstocks.com e-mail: info@standoutstocks.com WWW: http://www.standoutstocks.com

((M2 Communications disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to info@m2.com.

Related terms: acquisition, architecture, bandwidth, biology, biomedical, biotechnology, bonds, broker, business, california, cancer, ceo, clinical, commercial, community, computer, conference, corporate, dealer, economy, email, e-mail, environment, equity, europe, exercise, expansion, exploration, family, fire, germany, government, indiana, investment, investment opinion, java, lawsuit, library, linux, manufacturing, marketing, merger, nasdaq, networking, new york, north carolina, online, operating system, partnership, pharmaceuticals, physics, president, prices, products, prostate cancer, research, restructuring, revenue, sales, science, securities, software, Stockholm, studio, subscription, sweden, technology, telecommunications, trial, university, weather, web, wireless